Navigation Links
Fusion presents low proliferation risk, experts conclude

American researchers have shown that prospective magnetic fusion power systems would pose a much lower risk of being used for the production of weapon-usable materials than nuclear fission reactors and their associated fuel cycle.

The researchers, from Princeton University, found that if nuclear fusion power plants are designed to accommodate appropriate safeguards, there is little risk of fissile materials being produced for weapons, either secretly or overtly.

Their results have been published today, 29 March, by IOP Publishing in the journal Nuclear Fusion.

In the study, the researchers undertook a quantitative assessment of the risks of proliferation the spreading of nuclear materials for use in weapons that could be associated with future magnetic fusion energy power systems in three different scenarios and compared them to the risks associated with nuclear fission.

Co-author of the study Alex Glaser summarizes: "We found that the proliferation risks from fusion are low compared with fission, assuming that IAEA safeguards are applied in both cases."

The three scenarios were: the clandestine production of weapon-usable material in an undeclared facility; the covert production of such material in a declared facility; and the production of material in a breakout scenario where the effort is not concealed.

Firstly, their findings showed that it is highly implausible that a small-scale nuclear fusion system could be built, and then operated, in a clandestine fashion to produce material for even one weapon in two years, due to the large size and power consumption of the facility that would be required; it would be clearly visible by, for example, the continuous power it would consume and ultimately have to dissipate at least some 40 MW.

In comparison, first-generation centrifuge plants used to produce highly enriched uranium for fission power plants are much less conspicuous and can be operated to produce material for one weapon per year with less than 0.5 MW of power, similar to many industrial operations.

The researchers then used a set of computer simulations to determine the quantities of weapons materials that could be produced with a commercial-size fusion power plant. While the production potential is significant in principle, it would be easy for inspectors to detect the covert production of weapon-usable material in a declared nuclear fusion power plant.

The final scenario examined was breakout, where weapon-usable material is produced as quickly as possible and without concealment. The researchers estimate that the minimum period that would be required after breakout to produce any weapon-usable material in a fusion power plant would be one to two months. They also note that fusion power plants require many supporting facilities, such as power inputs and cooling towers, which could potentially be shut down without risk of nuclear contamination, and therefore prevent material from being produced.

Contact: Michael Bishop
Institute of Physics

Related biology technology :

1. CareFusion Announces 510(k) Clearance and U.S. Launch of New Advanced Electrodiagnostic System
2. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
3. New material for thermonuclear fusion reactors
4. CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems
5. Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
6. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
7. CareFusion Reports First Quarter Fiscal 2012 Results
8. Harvest Technologies Announces Initial Enrollment in Its REVIVE-1 Trial (REtrograde Vascular Infusion of BMAC to ImproVe Heart FailurE)
9. Practice Fusion Expands Executive Team with New VP of Marketing and Senior Business Development Director
10. Practice Fusion Invites Health Researchers to Analyze This! Contest on Windows Azure
11. Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and CEO of Neurocrine Biosciences, will be presenting ... New York . ... website approximately 5 minutes prior to the presentation to ... the presentation will be available on the website approximately ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... United States ," said Andrew Rae ... advancements regarding iCo-008 are not only value enriching ...
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... 2015  The J. Craig Venter Institute (JCVI) policy ... and Biosecurity: Lessons Learned and Options for the Future," ... Human Services guidance for synthetic biology providers has worked ... --> --> Synthetic biology promises ... to pose unique biosecurity threats. It now is easier ...
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
Breaking Biology News(10 mins):